Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Ligand Pharmaceuticals has licensed the rights to five drug research programs to Viking Therapeutics, a biotech start-up specializing in metabolic and endocrine disorders. The deal includes Ligand’s FBPase inhibitor program for type 2 diabetes and its selective androgen receptor modulator (SARM) program for muscle wasting. Each program includes a payment to Ligand in Viking equity at the time of any outside financing, milestone payments, and royalties on future sales. Ligand will extend a $25 million loan to Viking to cover expenses.
This article has been sent to the following recipient: